Evaluation of immunogenicity, safety and reactogenicity of GSK Biologicals’ Boostrix vaccine administered as a booster dose in healthy Russian subjects

Trial Identifier: 201532
Sponsor: GlaxoSmithKline
Start Date: January 2018
Primary Completion Date: August 2018

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Russian Federation Barnaul, Russian Federation, 656056
Russian Federation Ekaterinburg, Russian Federation, 620137
Russian Federation Gatchina, Russian Federation, 188300
Russian Federation Moscow, Russian Federation, 129515
Russian Federation Moscow, Russian Federation, 115478
Russian Federation Murmansk, Russian Federation, 183038
Russian Federation Saint Petersburg, Russian Federation, 191025
Russian Federation Yaroslavl, Russian Federation, 150051